| Similar Articles |
|---|
 |
The Motley Fool
May 30, 2008
Brian Orelli |
WuXi Woos Pharma Pharmaceutical outsourcing specialist WuXi PharmaTech proves that outsourcing to China isn't dead yet and neither are Chinese companies moving stateside.   |
The Motley Fool
October 1, 2008
Brian Orelli |
WuXi and Covance Call It Quits WuXi PharmaTech and Covance broke up yesterday - just three months after announcing they'd form an alliance to perform pre-clinical research for drug developers looking for research and development on the cheap. |
The Motley Fool
April 27, 2010
Brian Orelli |
Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home. |
The Motley Fool
March 14, 2008
Brian Orelli |
No Slowdown for China's WuXi Chinese drug researcher and manufacturer WuXi signs more drug development deals and buys a U.S. manufacturing services company. |
The Motley Fool
June 25, 2008
Brian Orelli |
WuXi's Shortsighted Deal WuXi partners with Covance, but is it really a good long-term play? |
The Motley Fool
August 1, 2008
Brian Orelli |
Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit. |
The Motley Fool
October 23, 2009
Robert Steyer |
Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends. |
The Motley Fool
November 7, 2006
Brian Gorman |
Charles River Inches Forward The drug research services company is not out of the woods yet, but some positive signs are emerging. Investors, take note. |
The Motley Fool
May 13, 2008
Brian Orelli |
Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company. |
The Motley Fool
October 31, 2006
Brian Gorman |
Kendle's New Risk The drug development services company continues to deliver, but new debt poses some risk to future earnings. In the near term, investors could be in for a bumpy ride. |
The Motley Fool
August 9, 2006
Brian Gorman |
Charles River's Uptick The drug research services company looks better than it did last quarter, but it still has its issues. Investors, take note. |
The Motley Fool
November 12, 2009
Brian Orelli |
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way. |
The Motley Fool
April 20, 2011
Brandon Glenn |
Growing CRO Demand Boosts Outlook for Kendle It's been rough going lately for Kendle. |
The Motley Fool
March 6, 2009
Brian Orelli |
For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations. |
The Motley Fool
April 24, 2009
Robert Steyer |
Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services. |
The Motley Fool
July 30, 2009
Robert Steyer |
Covance Advances Covance latest results produce more optimism than did some of its contract research peers. |
The Motley Fool
November 1, 2005
Brian Gorman |
Kendle's Resurgence Can the contract pharmaceutical researcher continue its growth without more acquisitions? Despite the vibrant growth and its operational progress, Kendle still is at a disadvantage to larger rivals like Charles River Laboratories and PPD. |
The Motley Fool
May 10, 2006
Brian Gorman |
Charles River Restructures For the near term, restructuring plans should keep this one in limbo. Investors shouldn't expect too much from the company right now. |
The Motley Fool
July 22, 2004
Brian Gorman |
Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent. |
The Motley Fool
June 15, 2006
Brian Gorman |
Covance Gets Strategic The drug research service company's latest deal could help it cement its leadership in the industry. Investors, take note. |
The Motley Fool
October 3, 2011
Brian D. Pacampara |
Pharmaceutical Product Development Shares Soared: What You Need to Know Shares of Pharmaceutical Product Development skyrocketed 25% Monday after The Carlyle Group and Hellman & Friedman LP agreed to buy the health-care research specialist for $3.8 billion. |
The Motley Fool
December 27, 2007
Brian Orelli |
Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there. |
The Motley Fool
August 25, 2006
Brian Gorman |
California's Drug Demands As the pressure grows on drugmakers from legislation, growth and consolidation in the outsourcing business seem likely. |
The Motley Fool
August 13, 2007
Andrew R. Vaino |
Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow. |
The Motley Fool
January 27, 2005
Brian Gorman |
Covance's Higher Performance The provider of drug development services' productivity gains and bundled service strategy are driving results. |
The Motley Fool
April 28, 2006
Brian Gorman |
Speed Bumps at Covance Although some problems have cropped up, this drug-research services company is still a solid performer overall. Investors, take note. |
The Motley Fool
October 11, 2007
Billy Fisher |
An IPO That Hit the Bull's-Eye Sirtris Pharmaceuticals presents promising drug data and is turning out to be one of the top-performing IPOs in the biotech/pharmaceutical field in 2007. |
The Motley Fool
February 15, 2005
Brian Gorman |
Kendle Grows With Client Base The contract drug research company shares surged as the firm showed signs of new life. |
The Motley Fool
January 25, 2007
Brian Gorman |
Covance Stays Solid Despite a run-up in the stock, Covance may be in for yet another solid year. |
The Motley Fool
January 27, 2006
Brian Gorman |
Covance Keeps Humming The provider of drug research services will likely continue to deliver, even if one measure shows signs of tapering off. As a long-term investment, Covance looks like a good bet. |
The Motley Fool
February 14, 2006
Brian Gorman |
Kendle's on Solid Ground The contract research services outfit is on track for another good year. Investors, take note. |
The Motley Fool
December 28, 2007
Brian Orelli |
The Biggest Health-Care IPOs of 2007 Let's take a look at four of the most intriguing health care IPOs from 2007. |
The Motley Fool
November 12, 2009 |
3 Stocks Hitting High Notes These stocks are reaching for the stars and hitting 52-week highs. Take a look at: Dow Chemical... WuXi PharmaTech... Catalyst Health Solutions... |
